// App-Quantinova.ai

: Umeclidinium/vilanterol in preventing clinically important deterioration (CID) in COPD and impact of baseline disease severity: the EMAX trial

Researchers

Presenter

  • Claus Vogelmeier

Principal Investigators

  • Ian P. Naya

  • Lee Tombs

  • Edward M. Kerwin

  • Leif Bjermer

  • Isabelle H. Boucot

  • Paul Jones

  • David A. Lipson

  • Chris Compton

  • Franois Maltais

Medical Centers

  • Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universität Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany,

  • Global Respiratory Franchise, GSK, Brentford, Middlesex, United Kingdom,

  • Precise Approach Ltd, contingent worker on assignment at GSK, Stockley Park West, Uxbridge, Middlesex, United Kingdom,

  • Clinical Research Institute of Southern Oregon, Medford, OR, United States.

  • Respiratory Medicine and Allergology, Lund University, Lund, Sweden,

  • Respiratory Research and Development,GSK and Perelman School of Medicine, University of Pennsylvania, Collegeville and Philadelphia, PA, United States.

  • Centre de Pneumologie, Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Quebec, QC, Canada,

Locations

  • Germany

  • United Kingdom

  • United States

  • Sweden

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Umeclidinium

  • Salmeterol Xinafoate

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Parallel Group

Phase

  • NA

Study Id's

  • NCT03034915

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved